Epilepsia Open最新文献

{"title":"Attitudes toward sodium valproate use, withdrawal, and counseling in people of reproductive potential: A scoping review.","authors":"Katherine Wang, Sarah Loveday, Monica S Cooper, Emma Macdonald-Laurs","doi":"10.1002/epi4.70342","DOIUrl":"https://doi.org/10.1002/epi4.70342","url":null,"abstract":"<p><p>Regulatory restrictions and evolving clinical guidelines have aimed to reduce sodium valproate use in people of reproductive potential over the past decade due to its teratogenic risk. While clinical evidence and policy responses are well established, stakeholder perspectives remain less explored. This scoping review synthesizes the existing evidence on the attitudes of patients, caregivers and healthcare professionals regarding sodium valproate use, withdrawal and counseling in females of childbearing age. This scoping review, conducted according to JBI Methodology for a Scoping Review and registered on Open Science Framework (https://doi.org/10.17605/OSF.IO/HK7QN), analyzed studies which directly reported on, or measured, the attitudes of patients, caregivers and/or healthcare professionals regarding the use of sodium valproate for epilepsy in females. A structured search across four databases (EMBASE, Web of Science, MEDLINE, PsycINFO) and the gray literature was performed. A thematic synthesis of data was conducted to identify important themes and concepts. A total of 22 studies including 14 peer-reviewed articles and 8 gray literature sources met the inclusion criteria, including only 2 qualitative studies. Most literature focused on patient and caregiver perspectives (n = 15), with fewer addressing healthcare professional views (n = 7). Methodology incorporating interviews (n = 2) or free-text survey responses (n = 3) was uncommon. Across the studies, three key themes emerged: (i) patient disempowerment due to limited knowledge and suboptimal counseling and risk communication; (ii) the influence of maternal identity formation on attitudes, behaviors and decision-making when navigating sodium valproate use; and (iii) concerns regarding regulatory responses, such as pregnancy prevention programs, particularly around implementation challenges, perceived paternalism and lack of individualized care. Published evidence on stakeholder attitudes toward sodium valproate use in people of reproductive potential remains limited. The existing literature highlights gaps in awareness, counseling, and patient-centered delivery of pregnancy prevention programs. Future research should prioritize qualitative studies to better understand stakeholder attitudes and experiences to inform future guidelines and clinical practice. PLAIN LANGUAGE SUMMARY: Sodium valproate is an antiseizure medication that can harm an unborn baby when used during pregnancy. National and international programs have been introduced to reduce its use among people who could become pregnant. This review explored the perspectives of patients, caregivers and healthcare providers regarding sodium valproate use and withdrawal. Key themes included experiences of disempowerment relating to risk communication, the influence of maternal identity on treatment decisions and concerns about regulatory approaches. These findings highlight factors contributing to challenges with pregnancy preventi","PeriodicalId":12038,"journal":{"name":"Epilepsia Open","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13496280/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148789884","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"DECREASE study: A European pool-analysis of patients with significant reductions in concomitant antiseizure medications in cenobamate Early Access Programs.","authors":"Vicente Villanueva, Simona Lattanzi, Javier Peña-Ceballos, Rhys H Thomas, Juan Rodríguez-Uranga, Zsófia Jordán, Bernhard J Steinhoff, Randi von Wrede, Norman Delanty, Patrick B Moloney, Roberta Roberti, Giovanni Boero, Laura Canafoglia, Nicola Specchio, Antonio Gambardella, Edoardo Ferlazzo, Francesca Felicia Operto, Elena Tartara, Hester Garratt, Dániel Fabó, Asier Gómez-Ibáñez, Gustavo Torres-Gaona, Yulia Novitskaya, Rainer Surges, Kevin Hampel, Andreas Schulze-Bonhage","doi":"10.1002/epi4.70344","DOIUrl":"https://doi.org/10.1002/epi4.70344","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the effectiveness and tolerability of cenobamate in patients with a significant reduction in concomitant antiseizure medication (ASM) in European cenobamate Early Access Programs (EAPs).</p><p><strong>Method: </strong>Anonymized patient data from real-world studies/registries associated with European cenobamate EAPs were pooled. Patients were included if they had significantly reduced their concomitant drug load (i.e., converted to cenobamate monotherapy or reduced from multiple to one concomitant ASM) between baseline and the last visit. Effectiveness, tolerability, and dosage of cenobamate were evaluated. Responses according to therapeutic regimen at last visit were studied.</p><p><strong>Results: </strong>Of 694 patients within cenobamate EAPs, 75 (10.7%) met the inclusion criteria (mean age 39.5 years [range 19-65]). At baseline, the median number of prior ASMs was 10 (interquartile range [IQR] 6-13); 46 patients (61.3%) were taking two, 23 (30.7%) were taking three, and six (8%) were taking four concomitant ASMs at baseline. At the last visit, seven patients (9.3%) were converted to monotherapy and 68 (90.7%) were receiving one concomitant ASM. The median cenobamate dosage at last visit was 300 mg (IQR 200-350). Median cenobamate follow-up was 22 months; 73 patients (97%) had at least 1 year of follow-up and one discontinued cenobamate at 1 year. Twenty-five patients (33.3%) were seizure-free at last visit; 51 (68%) had a ≥50% reduction in seizure frequency. The seizure-freedom rate was numerically, but not significantly, higher in patients converted to monotherapy (57.1%) versus those receiving one concomitant ASM (30.9%; p = 0.16). Cenobamate plus clobazam was the most effective combination. Adverse events (AEs) were reported in 55/75 patients (73.3%); the most common were somnolence (30.7%), dizziness/vertigo (28%), and fatigue (26.7%). No AEs led to treatment discontinuation.</p><p><strong>Significance: </strong>Cenobamate demonstrated good effectiveness and tolerability in a population of patients within European EAPs who achieved a significant reduction of concomitant ASM.</p><p><strong>Plain language summary: </strong>People with highly drug-resistant epilepsy often need to take several antiseizure medications at the same time. Combined data from European Early Access Programs show that about 10% of people treated with cenobamate were able to stop all other antiseizure medications or reduce treatment to cenobamate plus one other medication. Despite this simplification of treatment, one-third of these patients became seizure-free and more than two-thirds experienced at least a 50% reduction in seizure frequency. Within this group, no patients stopped cenobamate because of side effects.</p>","PeriodicalId":12038,"journal":{"name":"Epilepsia Open","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13494722/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148789889","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"EEG CONNECT: A proposed reporting checklist for EEG-based connectivity studies in clinical epilepsy research.","authors":"Naoto Kuroda, Ethan Firestone, Giulia Sofia Cereda, Jesús Servando Medel-Matus, Pedro F Viana, Aristea S Galanopoulou, Eishi Asano","doi":"10.1002/epi4.70343","DOIUrl":"https://doi.org/10.1002/epi4.70343","url":null,"abstract":"<p><p>EEG-based connectivity analysis has emerged as a promising approach for investigating brain network dynamics in clinical epilepsy research. However, the diversity of analytical approaches, preprocessing pipelines, and reporting practices poses challenges to reproducibility and clinical translation. Existing guidelines such as STROBE and GREENBEAN provide valuable frameworks for clinical research and EEG-based biomarker reporting, but they were not designed to address the methodological complexities unique to EEG-based connectivity studies. To address this gap, we propose the Electroencephalography-based Connectivity Studies Evaluation Checklist for Clinical Epilepsy Research (EEG CONNECT), a proposed 24-item reporting checklist tailored to EEG-based connectivity analysis. This checklist covers key elements of study design, data acquisition, analysis methods, and interpretation, and is applicable to both scalp and intracranial EEG. To evaluate current reporting practices and explore the feasibility of the proposed checklist, we conducted a systematic review of 45 peer-reviewed clinical studies published between 2022 and 2024 that used one of four connectivity analysis methods: coherence, transfer entropy, Granger causality, and neural responses to single-pulse electrical stimulation. Articles were assessed based on whether each checklist item was sufficiently, partially, or not reported. The overall mean reporting adherence was 70.3% (standard deviation ±12.9%). Items related to connectivity estimation approach, biological plausibility, and methodological limitations were most frequently underreported. Checklist adherence was correlated with the publishing journal's impact factor (Spearman's rho = 0.358, p = 0.018) and with article citation rate (rho = 0.363, p = 0.014). These findings underscore the need for standardized reporting in EEG connectivity research. EEG CONNECT is a proposed practical framework to support systematic methodological reporting, although its use is not intended to be mandatory. Adoption of this checklist may facilitate comparisons across studies and support the translation of EEG-based connectivity findings into improved understanding and treatment of epilepsy and other brain disorders. PLAIN LANGUAGE SUMMARY: EEG connectivity analysis can help researchers understand how different brain regions interact in epilepsy, but reporting practices vary across studies. We developed EEG CONNECT, a proposed 24-item checklist to support clearer and more consistent reporting of EEG connectivity research. We applied the checklist to 45 recent clinical studies and found that several important methodological details were often underreported, particularly how connectivity was estimated, its biological plausibility, and methodological limitations. EEG CONNECT provides a practical framework that may improve transparency, facilitate comparisons across studies, and support the clinical translation of EEG connectivity research.</p>","PeriodicalId":12038,"journal":{"name":"Epilepsia Open","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13487411/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148789898","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The genetic architecture of epilepsy across molecular mechanisms and clinical heterogeneity.","authors":"Mohammad Reza Seyedtaghia, Jina Babanzadeh, Marcello Scala, Lorenzo Perilli, Pasquale Striano","doi":"10.1002/epi4.70310","DOIUrl":"https://doi.org/10.1002/epi4.70310","url":null,"abstract":"<p><p>Epilepsy comprises a highly heterogeneous group of neurological disorders unified by a persistent predisposition to recurrent seizures, yet driven by remarkably diverse genetic, molecular, and network-level mechanisms. Advances in genomic technologies have revealed that epilepsy arises from a multilayered genetic architecture encompassing rare high-penetrance monogenic variants, common polygenic risk factors, brain-restricted somatic mosaicism, and extensive gene-environment interactions. These genetic substrates converge on core biological pathways regulating neuronal excitability, synaptic transmission, metabolic homeostasis, neuroinflammation, and circuit development. In this review, we synthesize contemporary insights into the genetic and molecular pathophysiology of seizures and epilepsy, with emphasis on mechanisms that destabilize excitation-inhibition balance, promote epileptogenesis, and drive pharmacoresistance. We highlight how ion channel dysfunction, synaptic vesicle cycling defects, mTOR pathway hyperactivation, glial and metabolic failure, and inflammatory cascades interact to lower seizure threshold and remodel neural networks. Beyond classical monogenic and polygenic models, we discuss the emerging role of somatic mutations, polygenic modifiers of rare variants, and dynamic brain-state-dependent seizure susceptibility. We further integrate genetic mechanisms with clinical heterogeneity, including age of onset, seizure type, penetrance, pleiotropy, and treatment response, and review translational implications for precision medicine, pharmacogenomics, and emerging molecular therapies such as antisense oligonucleotides, gene regulation strategies, and cell-based interventions. Understanding the genetic architecture of epilepsy is increasingly informing diagnostic pathways, prognostic stratification, and the development of precision-based therapeutic approaches. PLAIN LANGUAGE SUMMARY: Epilepsy genetics extends beyond single-gene disorders and involves multiple interacting layers of genomic variation. In this review, we integrate evidence across rare variants, polygenic risk, somatic mosaicism, and genetic modifiers to provide a broader framework for understanding seizure susceptibility and clinical diversity. By highlighting convergent biological pathways and their effects on neuronal networks, this work supports more refined approaches to epilepsy classification and future precision medicine strategies.</p>","PeriodicalId":12038,"journal":{"name":"Epilepsia Open","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13487861/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148789938","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A smart mattress for detecting and correcting the prone position: A feasibility study toward night-time SUDEP prevention.","authors":"Jong Woo Lee, Pranav Bansal, Ioannis Smanis, Justin Nguyen, Ellen Pritchard, Janet Orozco, Andres Rodriguez","doi":"10.1002/epi4.70329","DOIUrl":"https://doi.org/10.1002/epi4.70329","url":null,"abstract":"<p><strong>Objective: </strong>Sudden unexpected death in epilepsy (SUDEP) is the leading cause of death in otherwise healthy patients with epilepsy; about 70% occurs during sleep, and nearly 90% of patients are found prone (face-down). Following a nocturnal seizure, terminal apnea occurs between 2.5 and 10.8 min postictally (median ~ 5 min), defining a narrow but actionable window for intervention. Although body-position sensors are well established in sleep medicine and have been applied in epilepsy, no current product combines prone-position detection with autonomous repositioning into a recovery (sideways) position.</p><p><strong>Methods: </strong>Korus is a smart mattress made of an array of inflatable cells. Korus consists of a sensor system to rapidly detect body change with high accuracy and a grid of expandable cells that reposition a patient from the prone to the recovery position.</p><p><strong>Results: </strong>Ten normative control subjects were recruited, nine of whom were systematically tested. Each Korus cell generated a lift of 454 kg/cell at 5 cm/s. The sensor array detected body position changes within 5 s. Manually controlling the cells to reposition the subject from prone to recovery was successful in 100% of attempts in an average of 21.75 (±5.85) seconds. Body position detection was 96.8% accurate in detecting the prone position and 92.4% accurate overall in detecting the correct body position (supine, prone, left, right). False body position detection rate was 2.3 events/h. There were no incorrect position detections when subjects switched into the prone position.</p><p><strong>Significance: </strong>This study demonstrates the feasibility of developing a smart mattress to detect the prone position and rapidly reposition subjects into a recovery position. Future development includes a control system to automate repositioning based on sensor data. The Korus device, when paired with a seizure detection device, may help lower the risk of night-time SUDEP, though the magnitude of any benefit remains to be established.</p><p><strong>Plain language summary: </strong>Sudden unexpected death in epilepsy (SUDEP) most frequently occurs at night, and the prone position is a major risk factor. A device to autonomously reposition a patient to the recovery position may markedly reduce the rates of SUDEP. Here we describe the Korus, a smart mattress with the ability to reposition patients out of the prone position in their sleep.</p>","PeriodicalId":12038,"journal":{"name":"Epilepsia Open","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13484912/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148789541","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"From first seizure to specific antiseizure medication in Dravet syndrome: Quantifying delays in the DS'coverED study.","authors":"Loucas Christodoulou, Maria Ballarà Petitbò, Sergio Aguilera Albesa, Simona Borroni, Perrine Hugon, Ratna Kumar, Tullio Messana, Pierre Meyer, Frédéric Villéga, Kerstin A Klotz","doi":"10.1002/epi4.70328","DOIUrl":"https://doi.org/10.1002/epi4.70328","url":null,"abstract":"<p><strong>Objective: </strong>Dravet syndrome (DS) is a rare early-onset developmental and epileptic encephalopathy with persistent delays between seizure onset and diagnosis. The DS'coverED study aimed to characterize current diagnostic timelines by examining each step and its duration, identifying residual barriers, and actionable solutions to optimize the diagnostic process within real-world clinical pathways.</p><p><strong>Methods: </strong>A steering committee-eight pediatric neurologists and one representative from the DS European Federation-developed a survey addressed to European pediatric neurologists experienced in DS management. Responders reported information on their medical practice and data on patients' diagnostic pathways from seizure onset to initiation of DS-specific antiseizure medications (ASMs).</p><p><strong>Results: </strong>Fifty-three physicians participated in the study. Analysis of 45 patient diagnostic pathways revealed marked heterogeneity in the DS diagnostic pathway. The median age at formal diagnosis was 15 months, with a median interval of 11 months between seizure onset and diagnosis. While half of the patients received a diagnosis within 1 year of seizure onset, 25% were diagnosed after 23 months of age. Diagnostic delays were primarily associated with late referral to expert centers and prolonged access or turnaround times for genetic testing. Although 45% of responders requested genetic testing promptly after initial consultation, more than half waited for confirmatory results before formally communicating the diagnosis. Initiation of DS-specific ASMs was inconsistent-occurring a median of 3 months after diagnosis but exceeding 9 months in 27% of cases-likely influenced by clinician caution, drug availability, and parental concerns regarding the treatment regimen.</p><p><strong>Significance: </strong>DS'coverED seeks to fill a critical knowledge gap in the DS diagnostic pathway. The study provides healthcare professionals with benchmarks for refining their diagnostic practices and guiding clinical improvements-ongoing clinician education, better healthcare system coordination, and active caregiver engagement.</p><p><strong>Plain language summary: </strong>The diagnosis of Dravet syndrome, a rare and severe form of childhood epilepsy, is still often delayed after the first seizure. The DS'coverED European survey explored each step of the diagnostic journey and identified residual barriers and opportunities to optimize the time to diagnosis and access to Dravet syndrome-specific antiseizure medications. It provides physicians with actionable solutions that can help improve the diagnostic process of the condition.</p>","PeriodicalId":12038,"journal":{"name":"Epilepsia Open","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13473756/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148758895","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Beyond seizure freedom: Reframing recovery in epilepsy.","authors":"Giancarlo Di Gennaro, Andrea Tomasini","doi":"10.1002/epi4.70341","DOIUrl":"https://doi.org/10.1002/epi4.70341","url":null,"abstract":"","PeriodicalId":12038,"journal":{"name":"Epilepsia Open","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13473195/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148760059","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of vigabatrin on risk of relapse of infantile spasms.","authors":"Yaretson I Carmenate, Hayoung E Ahn, Haley R Peters, Hiroki Nariai, Rajsekar R Rajaraman, Shaun A Hussain","doi":"10.1002/epi4.70338","DOIUrl":"https://doi.org/10.1002/epi4.70338","url":null,"abstract":"<p><strong>Objective: </strong>Vigabatrin is an effective treatment for infantile epileptic spasms syndrome (IESS), but relapse remains a clinical challenge. The ideal dose and duration of treatment after response are unknown. We set out to identify treatment-related predictors of IESS relapse after initial vigabatrin response.</p><p><strong>Methods: </strong>We conducted a retrospective cohort study of infants with IESS who achieved electroclinical response within 30 days of vigabatrin initiation (alone or with hormonal therapy) and remained in remission for ≥ 30 days. Time to epileptic spasms relapse was analyzed using the Kaplan-Meier procedure and Cox proportional hazards regression. A linear regression-based propensity score (derived from etiology and latency to vigabatrin initiation) was included in Cox models to adjust for treatment duration confounding. Candidate predictors included age at IESS onset, presence of other seizure types at onset, developmental status, prior relapse, vigabatrin dose, and use of dual therapy (concomitant adrenocorticotropic hormone [ACTH] or prednisolone).</p><p><strong>Results: </strong>Of 164 responders, 63 (38%) relapsed at a median of 7.5 months (IQR: 2.4-18.0) after response. Twenty-one (33.3%) relapses occurred following vigabatrin discontinuation. In propensity score-adjusted multivariable regression, increased relapse risk was associated with prior IESS relapse (HR 2.35; 95% CI 1.24-4.45; P = 0.009), other seizure types at IESS onset (HR 2.31; 95% CI 1.31-4.07; P = 0.004), and abnormal development at IESS diagnosis (HR 1.75; 95% CI 1.04-2.95; P = 0.035). Moderate dosing (100-149 mg/kg/day) was protective versus lower doses (HR 0.47; 95% CI 0.25-0.89; P = 0.020). In an underpowered analysis of vigabatrin exposure as a time-varying covariate, ongoing therapy was not significantly associated with latency to relapse (HR 0.77; 95% CI 0.39-1.49; P = 0.436).</p><p><strong>Significance: </strong>Relapse after vigabatrin response is common and influenced by identifiable clinical factors. Continued vigabatrin treatment (> 100 mg/kg/day) may reduce relapse risk. Prospective validation is warranted to guide individualized relapse prevention strategies.</p><p><strong>Plain language summary: </strong>Infantile Epileptic Spasms Syndrome is a serious seizure disorder of infancy that can recur even after successful treatment with vigabatrin. In this study of 164 infants, we found that relapse was most common among children with prior relapses, other seizure types, or developmental delays. Infants treated with moderate vigabatrin doses (100-149 mg/kg/day) had the lowest relapse rates. These findings may help clinicians identify which infants face the highest risk and tailor treatment accordingly.</p>","PeriodicalId":12038,"journal":{"name":"Epilepsia Open","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13472970/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148766407","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Interview with Ruotong Chen, recipient of the 2026 Epilepsia Open Prize for Clinical Research.","authors":"Merab Kokaia, Piero Perucca","doi":"10.1002/epi4.70321","DOIUrl":"https://doi.org/10.1002/epi4.70321","url":null,"abstract":"","PeriodicalId":12038,"journal":{"name":"Epilepsia Open","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13473754/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148757983","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Interview with Zining Liu, recipient of the 2026 Epilepsia Open Prize for Basic Science Research.","authors":"Merab Kokaia, Piero Perucca","doi":"10.1002/epi4.70322","DOIUrl":"https://doi.org/10.1002/epi4.70322","url":null,"abstract":"","PeriodicalId":12038,"journal":{"name":"Epilepsia Open","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13473753/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148757865","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}